Inspectors find more serious problems at Ohio CVS pharmacies

Inspectors find more serious problems at Ohio CVS pharmacies

https://ohiocapitaljournal.com/2023/08/25/inspectors-find-more-serious-problems-at-ohio-cvs-pharmacies/

From a lack of control over narcotics to expired drugs on the shelves, inspectors at the Ohio Board of Pharmacy have found more problems at what appear to be chronically understaffed CVS pharmacies.

The new inspection reports from four Ohio pharmacies are in addition to reports finding similar problems at nine others that the Capital Journal reported on in July. In those reports, inspectors described mass departures by frustrated, burnt-out employees who said they didn’t think they could do their jobs safely and didn’t feel supported by CVS management.

Several current and former CVS pharmacy employees made similar complaints to the Capital Journal and said that the corporation seemed to be more focused on maintaining profits than it was on protecting patients.

For its part, CVS maintains that it strives to uphold the highest standards of patient service and safety. 

“As we’ve previously stated, we’re working with the Board of Pharmacy to resolve allegations raised from prior inspections at select CVS Pharmacy locations, we have policies and procedures in place to support prescription safety, and we’re committed to ensuring there are appropriate levels of staffing and resources at our pharmacies,” spokeswoman Amy Thibault said in an email Friday.

But the pharmacy board seems skeptical. 

Earlier this month, it proposed sweeping new rules that were prompted in part by what it found in its inspections of Ohio CVS stores. An important one is aimed at limiting wait times for prescriptions to be filled to 72 hours after inspection reports found numerous 14-day waits and some that were as long as a month.

One of the newly released inspection reports details the unexplained loss last year of nearly 1,000 doses of controlled substances at CVS store No. 16660 in Rossford, a Toledo suburb. They include 499 doses of Alprazolam, also known as Xanax, and 275 doses of Hydrocodone and Oxycodone.

The report said that the loss of 413 Alprazolam tablets was discovered on Nov. 12, 2021, but not reported until Jan. 4, 2022, nearly two months later.

On April 14, an inspector spoke to CVS’s asset protection leader about the losses. That person said they “were due to operational error at the pharmacy. He did not know why the losses were reported months after discovery. He reported the losses to CVS’ regulatory office and the office later reported to the Board,” the report said.

CVS, which owns the largest pharmacy retail chain in the United States, has been accused of using other business units to cut drug reimbursements in order to drive smaller competitors to sell out to CVS. Regardless of whether that’s actually the case, CVS for the past five years has been buying up and closing its competitors and moving prescriptions at those pharmacies to existing CVS stores.

In 2021, CVS also announced that it would also close 900 of its own stores in the United States over the next three years and move those prescriptions to remaining CVS locations as well.

But as it has heaped loads of new work onto its remaining pharmacies, it’s unclear whether it’s added staffing to help deal with the extra work.

A Board of Pharmacy report dated Aug. 16 said that Store No. 6153 in Columbus “absorbed prescriptions from CVS No. 342 which closed in August 2022.”

It added that the consolidation increased the prescription workload by at least 63%.

“The pharmacy went from filling 2,500 to 2,700 prescriptions per week to filling 4,400 prescriptions the week ending October 15, 2022,” it said.

A Dec. 8, 2022 inspection found conditions consistent with under-staffing. 

  • “Drug shelves were dusty, cluttered, and overflowing.”
  • “Pharmacy aisles were lined with stock bottles and trash (prescription inserts, foils, bits of paper, and loose pills).”
  • “There were 1,372 prescriptions in the work queue. The pharmacy dispenses an average of 700 prescriptions per day. The pharmacy was five days behind in the work queue.”

Thibault, the CVS spokeswoman, didn’t answer directly when asked whether the store added staff after it absorbed 63% more prescriptions from store No. 342. Similarly, the company’s spokespeople wouldn’t respond directly to earlier employee claims that they’re frequently told to cut hours even when employees are available and that district and regional managers receive bonuses based in part on keeping down labor costs.

Another of the reports released last week indicates similar cluttered, dirty conditions that could be related to under-staffing — this time at CVS store No. 6183 in Springfield. It also underscored how high turnover that is often associated with under-staffing can lead to the lack of controls over dangerous drugs.

During an inspection on Feb. 1, inspectors found that an inventory of controlled substances hadn’t been conducted since the previous April. That was the case even though there was a change of “Responsible Person,” or head pharmacist, in December and one was required to be done then.

A former CVS pharmacist last month told the Capital Journal that the lack of such controls — along with erratic double-checks called “cycle counts” — could allow narcotics to disappear from pharmacy shelves in a way that’s impossible to trace.

Yet another inspection report released last week details further problems likely associated with under-staffing at CVS store No. 6086 in Lebanon.

On Sept. 29, 2022, inspectors found “multiple expired drugs, including Colesevelam hydrochloride 626mg, armour thyroid 2 grain tablets, quinapril 40mg tablets, and quetiapine 200mg tablets, were in the active drug stock. They had expired between June 1, 2022 and August 30, 2022.”

After a subsequent inspection, they told the pharmacist in charge, “On or about October 20, 2022, you dispensed expired heparin 5000u/mL injections to Patient A.B. Patient A.B. administered one dose of the expired heparin 5000u/mL injection.”

Heparin is a blood thinner and if it’s expired, it can put an unsuspecting patient at risk by being less effective. Even so, a follow-up visit on Nov. 7, 2022 indicated that the problem with expired drugs persisted.

“Multiple expired drugs, including creams and ointments, were in the active drug stock,” the report said. “They had expired between August 2022 and October 2022.”

It’s not only CVS that seems reluctant to staff pharmacies at adequate levels. Opinion polling submitted by the Board of Pharmacy along with its proposed rule changes suggests that it’s a problem among the big chains, with their obsession with profits and relentless cost-cutting.

One was a 2021 survey asking Ohio pharmacists whether they agreed with the statement, “I feel that the workload-to-staff ratio allows me to provide for patients in a safe manner.” 

Almost 90% of those working for large chains responded that they didn’t have enough staff to keep patients safe. By contrast, almost three quarters of small-chain and independent pharmacists said they were adequately staffed to protect patients.

 

Heads up on the Presidential candidates

I am watching the Republican Presidential debates and Asa Hutchinson undefined just stated that he was former HEAD OF DRUG ENFORCEMENT ADMINISTRATION Under the George W Bush (43) administration

https://en.wikipedia.org/wiki/Asa_Hutchinson

When Ron DeSantis ran for Governor of FL in 2018 and the person running for Attorney General was married to a DEA AGENT. Of course, apparently I did not reach enough people or none paid attention, because she got elected.

TIMOTHY E. KING, MD AND “THE RISE OF NEO-EUGENICS” (MINDSET OF A SERIAL KILLER, MINDSET OF A MENGELE) MEDICAL COMMUNITY DEMANDS CONGRESSIONAL INVESTIGATION

Repeatedly appearing as an expert witness for the prosecution in the Eastern District, Dr. King’s biased and misleading statements raised concerns about potential conflicts of interest. It is argued that he operates as a medical fig leaf for prosecutors, who use his testimony to support their narrative on opioid use, often disregarding differing medical opinions.

TIMOTHY E. KING, MD, DEFRAUDING TAXPAYERS OF $BILLIONS, AND “THE RISE OF NEO-EUGENICS” (MINDSET OF A SERIAL KILLER, MINDSET OF A MENGELE) MEDICAL COMMUNITY DEMANDS CONGRESSIONAL INVESTIGATION

CVS stock plunges after Blue Shield of California drops retailer’s pharmacy services to save on drug costs

CVS stock plunges after Blue Shield of California drops retailer’s pharmacy services to save on drug costs

https://www.msn.com/en-us/money/companies/cvs-stock-plunges-after-blue-shield-of-california-drops-retailer-s-pharmacy-services-to-save-on-drug-costs/ar-AA1fp04L

Shares of CVS Health plunged 9% on Thursday after Blue Shield of California said it will drop the company’s pharmacy benefit management services and instead partner with Mark Cuban’s Cost Plus Drugs company and Amazon Pharmacy to save on drug costs for its nearly 5 million members. 

The announcement hints at the potential for health insurers to abandon the traditional pharmacy benefit manager, or PBM, system and sent shares of other companies that offer PBM services lower.

Cigna and UnitedHealth Group dropped about 7% and 1%, respectively. 

PBMs maintain lists of drugs covered by health insurance plans and negotiate drug discounts with manufacturers. But they have recently come under scrutiny from lawmakers for their role in inflating drug prices and causing health-care costs to skyrocket. 

CVS Health’s Caremark has been Blue Shield’s PBM partner for more than 15 years. 

Blue Shield will now work with five different companies to provide “convenient, transparent access to medications while lowering costs.”

Blue Shield CEO Paul Markovich said the plan, which is scheduled to fully launch in 2025, could save the company up to $500 million annually. 

Amazon Pharmacy will offer at-home drug delivery. Cuban’s Cost Plus Drug Company will provide access to low-cost medications through retail pharmacies. Another company, Abarca Health, will process drug claims.

Blue Shield will retain CVS Caremark for its specialty pharmacy services, which provide specialized therapies and counseling to patients suffering from complex disorders. 

“We look forward to providing care for Blue Shield of California’s members who require complex, specialty medications — as we have for nearly two decades,” said Michael DeAngelis, a spokesman for CVS Health, in a statement to CNBC.

Still, the loss of Blue Shield’s PBM partnership is another blow to Caremark, which is also set to lose a contract with Centene next year.

Just Imagine: being on Medicaid and a chronic pain pt and expecting to receive appropriate healthcare

The Doctor Won’t See You Now

Provider access is a major challenge for Medicaid patients

https://www.medpagetoday.com/opinion/second-opinions/105876

Patients are increasingly alarmed by the health workforce shortages delaying care, reducing access, and in some cases harming patient safety and quality of care.

Policymakers usually rely on provider counts to estimate and address shortage areas. However, we know that not all providers accept all types of insurance.

More specifically, the greatest shortfall of available providers is experienced by some of the poorest and sickest among us. Nearly 94 million people are covered by Medicaid, and secret shopper studies and physician reported surveys show that doctors are less likely to accept patients with Medicaid compared to those with private insurance or even Medicare.

We know that simply having health insurance is not enough; we also need more healthcare providers willing to see Medicaid patients.

Newly available Medicaid claims data (T-MSIS) now allow us to systematically track providers that serve Medicaid patients, as well as those that don’t. The data on primary care providers is displayed on our Medicaid Primary Care Workforce Tracker, where consumers can view trends over time, by specialty type, at a national, state, and county level.

As we report in the forefront section of the journal Health Affairs, the Tracker reveals a mix of good and bad news for Medicaid patients across the nation. In 2019, the percent of primary care physicians who provided any appreciable care to Medicaid patients — seeing just 11 or more patients over the year — ranged from 84% in Wisconsin to as low as 61% in New Jersey, suggesting the variability in state Medicaid policies matters a great deal.

Overall, the number of any type of primary care provider who saw Medicaid patients rose 13% from 2016 to 2019. However, advanced practice nurses and physician assistants made up 95% of the increase. The increase in physicians was only 1%, and the number of ob/gyns seeing Medicaid patients actually dropped 2.5% over the 3-year period, with 24 states losing ob/gyns accepting Medicaid over this period.

In 2019, 44% of U.S. counties had no Medicaid ob/gyns at all. Given that access to pre- and post-natal care can prevent life-threatening complications, this statistic translates to women dying in childbirth and other shameful health outcomes.

Thirteen states also saw a loss of Medicaid family medicine physicians, 21 states saw a loss of Medicaid internal medicine physicians, and 11 states saw a loss of Medicaid pediatricians.

There are many reasons healthcare providers and practices refuse or limit Medicaid patients. Across the U.S., state Medicaid programs pay on average 72% the rate of Medicare, and on top of the low pay, many providers cite other barriers to participation including loads of paperwork.

The federal government does require states to establish access standards for Medicaid managed care programs. However, enforcement by state agencies is variable and historically, there has been little oversight

In 2020, CMS issued a rule requiring states to develop quantitative network adequacy standards. Earlier this year, the Biden-Harris administration proposed new rules to establish national standards for appointment wait times and to require states to conduct secret shopper surveys to verify state compliance. These are important steps forward, but will require vigilance to ensure enforcement.

Overall health workforce shortages also limit the number of providers Medicaid may draw from. These shortages are only getting worse due to burnout and moral injury. In communities with too few resources, there are too few healthcare providers. It’s always those with the least who suffer the most.

During the COVID-19 pandemic, health workforce programs saw increasing investments. Programs like the National Health Service Corps — which places primary care and mental health providers in underserved settings in exchange for loan repayment — and the Teaching Health Centers program — which supports community-based physician and dental residency training programs — received American Rescue Plan Act funding. The federal government and states passed emergency policies to support telehealth and to allow advanced practice nurses and physician assistants to practice at their full scope. However, with the end of the COVID-19 public health emergency and the recent debt ceiling deal claw-back of unspent COVID relief funds, these programs are at risk again.

Among the lessons of COVID-19 is the importance of caring for America’s essential workers who keep our society functioning. These workers are often poorly paid and therefore rely on programs like Medicaid. It was also this population that (on top of pre-existing disparities) faced the brunt of COVID illness and death.

To ensure access to healthcare for women, children, essential workers and others, we need more providers willing to see Medicaid patients. Policymakers can help make that happen with better pay and a reduction in the administrative burdens associated with the program.

Such action would be a small price to pay for a healthier population — and a much stronger workforce.

Patricia Pittman, PhD, is the director of the Fitzhugh Mullan Institute for Health Workforce Equity, which is based at the George Washington University Milken Institute School of Public Health, and a professor of health policy and management. Candice Chen, MD, MPH, is a member of the Mullan Institute, and an associate professor of health policy and management at the George Washington University and a board-certified pediatrician.

exploring the National Pain Strategy and the CDC Guidelines

Here we start our journey into exploring the National Pain Strategy and the CDC Guidelines. Since the release of Violation of A Nation in April 2019, we continued our search for information and found more information that supported our report. Come join us as we unveil the story of how we found out that the CDC Guidelines were a part of the National Pain Strategy. Also, we discuss the opposition and other “advocates” in the community that have tried to disrupt our work. This is part one of a three part series. Thank you for joining us! You can find documentation of this work on our twitter account and on our website at www.ciaag.net Below is the link to the document that we wrote about the NIH meeting. http://9thx.mjt.lu/nl2/9thx/5qy19.htm…

taking the DEA to task over raiding doctor David Bockoff’s office

This video is in regards to a lawsuit filed by some of doctor David Bockoff’s pts after his office was raided and shutdown by the DEA late in 2022. https://www.pharmaciststeve.com/summary-dea-raid-dr-bockoffs-office-3-dead-1-15-million-cash-confiscated-from-doc-will-be-hear-about-future-deaths/  there is a lot of information in this video and one important information point is concerning all of these chronic pain pts technically being abandoned by actions of the DEA.

What came to my mind is that those agreements with those 3 major drug wholesalers and 3 major chain pharmacies (CVS, Walmart, Walgreen) that those corporation signed and agreement that they would sell fewer controls to all pharmacies and those three pharmacies would dispense fewer controls.

https://www.pharmaciststeve.com/dea-surrogates-are-trying-to-throttle-the-availability-of-controlled-meds-to-pts/

Here is the SMOKING GUN to prove civil rights violations – could support a class action lawsuit – but the community needs to stand up

Is this an intentional abandoning a certain number of pt who have a medical necessity for controlled meds?Atch 1 – Opening Brief – Petition for Review – Snyder v. Garland – 23-1007 – 8-7-2023 Official Filing (3)Atch 1 – Opening Brief – Petition for Review – Snyder v. Garland – 23-1007 – 8-7-2023 Official Filing (3)

Atch 3 – 2023 CA pain-guidelines

BRANDY R. MCMILLION’S ABSURDITY OF LAW, ABUSE OF POWER, MISUSED OF AUTHORITY: ARTICLE FILED IN OPPOSITION TO HER NOMINATION AS A FEDERAL JUDGE

Among the higher-profile cases that McMillion worked on was the prosecution of Dr. Rajendra Bothra of Bloomfield Hills, who faced charges in an alleged $500 million health care fraud scheme. Bothra was acquitted last year after spending three years in jail prior to his trial. Bothra was found not guilty of more than 40 federal counts along with his former employees, Ganiu Edu, David Lewis, Christopher Russo in what was considered one of the biggest losses for the U.S. Attorney’s Office in more than 10 years. The one-year anniversary of the acquittal is Thursday.President Joe Biden plans to nominate another Michigan prosecutor to the U.S. District Court for the Eastern District of Michigan, Brandy R. McMillion,

THE AMERICA AGONY: OPPOSING AUSA BRANDY R. MCMILLION’S NOMINATION TO FEDERAL JUDGESHIP: UNFIT TO SERVE: Part-1

 

Heart Failure Observed in T2DM Patients Who Used NSAIDs

Heart Failure Observed in T2DM Patients Who Used NSAIDs

https://www.uspharmacist.com/article/heart-failure-observed-in-t2dm-patients-who-used-nsaids

Previous research has demonstrated that fluid retention and endothelial dysfunction have been correlated with the use of NSAIDs, and T2DM ( type 2 diabetes ) has been associated with both a deterioration in kidney function and sub-clinical cardiomyopathy. In a recent study, researchers indicated that the short-term use of NSAIDs among patients with T2DM is correlated with a higher risk for heart failure (HF) hospitalization.

In the study published in the Journal of the American College of Cardiology, researchers “hypothesized that short-term use of NSAIDs could lead to subsequent development of incident heart failure (HF) in patients with T2DM.”

The analysis included data from Danish nationwide health registers for patients aged 18 to 100 years who were diagnosed with T2DM or initiated anti-diabetic treatment from 1998 to 2021. Study participants had no previous HF or rheumatic disease or filled NSAID prescriptions 120 days before diagnosis. Type 1 diabetes patients and women aged younger than 40 years who were only taking metformin (who might represent polycystic ovary syndrome rather than T2D) were excluded.

Follow-up commenced 120 days after T2DM diagnosis, and the patients were followed until first-time HF hospitalization, death, or December 31, 2021, whichever occurred first.

The primary exposure was a claimed prescription for an NSAID, and the researchers reported percentages of patients who claimed up to four prescriptions within 1 year from the start of follow-up. In the case-crossover analyses, the participants were considered exposed if an NSAID prescription was claimed within 28 days before the initial HF hospitalization.

The results revealed that of the 333,189 patients with T2DM, 44.2% were female, the average age was 62 years (interquartile range: 52-71 years) with 23,308 patients being hospitalized with HF during follow-up, and 16% of patients indicated the use of at least one NSAID prescription within 1 year.

Additionally, short-term use of NSAIDs was correlated with augmented risk of HF hospitalization (odds ratio [OR] 1.43; 95% CI, 1.27-1.63), most notably in subgroups aged ≥80 years (OR 1.78; 95% CI, 1.39-2.28), elevated hemoglobin A1c (HbA1c) levels treated with zero to one anti-diabetic drug (OR 1.68; 95% CI, 1.00-2.88), and without previous use of NSAIDs (OR 2.71; 95% CI, 1.78-4.23).

All-cause mortality after the initial HF hospitalization was reduced in patients exposed to NSAIDs compared with those who were not exposed to use of NSAIDs before HF hospitalization, with a 1-year standardized absolute risk difference (ARD) of –2.9% (95% CI, –5.3% to –0.4%), a 3-year ARD of –3.7% (95% CI, –6.9% to –0.5%), and a 5-year ARD of –3.9% (95% CI, –7.3% to –0.5%).

The authors concluded, “An elevated risk of HF was found when relating short-term NSAID use and first-time HF hospitalization using a self-controlled design with advanced age, elevated HbA1c levels, and no previous use of NSAIDs most strongly associated with first-time HF.”

Finally, the authors wrote. “Interestingly, the prognosis following incident HF for both NSAID-exposed and nonexposed was comparable. Individual risk assessment is advised if prescribing NSAIDs for patients with T2DM.”

The content contained in this article is for informational purposes only. The content is not intended to be a substitute for professional advice. Reliance on any information provided in this article is solely at your own risk.

Major Drug Wholesalers meeting the terms of agreement with 50 states’ Attorney Generals ?

Looks like those 3 major drug wholesaler’s agreement with those 50 states’ Attorney Generals are starting to get traction. The two quotes below, I don’t know if they are from a chain or a independent, but apparently the first – the reduction of your basic Norco 10/325 is only shipping 1/3 of the pharmacy normally uses per day.  Keep in mind that drug wholesalers only deliver FIVE DAYS A WEEK… So if this particular pharmacy is using 15 bottles a day – 7 days a week and they are only getting 5 bottles a day – 5 days a week. They are only getting abt 25% of what they normally use. That would suggest that some 255 pts are not going to be their month’s worth of  pain meds at just this ONE PHARMACY and will be some 30,000 doses short on this one med for ONE MONTH.
May be a Twitter screenshot of text that says 'r/pharmacy u/Jizzillionaire2 23h Norco Norco shortage Discussion Our wholesaler is limiting us to 5 of the 100-count 10/325 bottles per day in California. We normally go through about 15 bottles a day. Anyone else have this happening? This is really making things difficult. 65 54 Share ek_2024 23h Yes. We have had a lot of issues getting in norco. Specifically 7.5 and 10. We've also had some issues getting Percocet. It's scary. Not to mention how angry patients are getting at us'

diagram